Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival,…
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
calendar_today
September 3, 2026
domain
abbvie